Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete metabolic response or toxicities
Internal Medicine Journal · 2026-06 · 56 (6) · 976-982
DOI: 10.1111/imj.70415 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Internal Medicine Journal, online erschienen am 13.04.2026. Verfasst von Nur Sakinah Zulkifli und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunotherapy, Melanoma, Skin Neoplasms. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Checkpoint inhibitors (CPIs) have changed the treatment paradigm for patients with advanced melanoma, with significant improvement in overall survival. This study evaluated the outcomes of patients with advanced melanoma who were treated with CPI and had cessation of treatment due to either complete metabolic response (CMR) or toxicities.
Aims
To assess the outcomes of patients with advanced melanoma who ceased immunotherapy due to either CMR or toxicities.
Methods
A retrospective study of patients with unresectable stage III or IV melanoma who were treated by a single prescriber across two tertiary centres in Queensland. Patients were identified from hospital medical records and the chemotherapy prescribing programme. Data collected were analysed, and progression‐free survival (PFS) was evaluated.
Results
A total of 235 patients who ceased CPI due to either CMR or toxicities were included in this analysis. Of these, 182 patients (77.4%) ceased CPI due to CMR and 53 patients (22.6%) stopped due to treatment‐related toxicities. At median follow‐up of 48 months, the PFS was significantly longer in patients who ceased CPI following CMR compared to treatment‐related toxicities ( P = 0.0246). The 24‐month PFS and 48‐month PFS for patients who ceased CPI for CMR and toxicities were 87.6% versus 76.9% and 78.8% versus 62.8%, respectively, and 60.5% of patients had further response to therapy with rechallenged CPI upon progression.
Conclusions
Durability of responses is demonstrated in patients who ceased CPI due to either CMR or toxicities. In patients with disease recurrence, further response to CPI is possible. The option to discontinue CPI should be discussed with patients following CMR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
- Greenslopes Oncology, Cyril Gilbert Cancer Centre, Greenslopes Private Hospital, Brisbane, Queensland, Australia.
ORCID-Profile: Nur Sakinah Zulkifli
Zitieren
APA
Zulkifli, N. S., Tam, L., McLean, A., & Atkinson, V. (2026). Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete metabolic response or toxicities. Internal Medicine Journal, 56(6), 976-982. https://doi.org/10.1111/imj.70415
Vancouver
Zulkifli NS, Tam L, McLean A, Atkinson V. Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete metabolic response or toxicities. Internal Medicine Journal. 2026;56(6):976-982. doi:10.1111/imj.70415
BibTeX
@article{Zulkifli2026,
author = {Zulkifli, Nur Sakinah and Tam, Laura and McLean, Andrew and Atkinson, Victoria},
title = {Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete metabolic response or toxicities},
journal = {Internal Medicine Journal},
year = {2026},
volume = {56},
number = {6},
pages = {976--982},
doi = {10.1111/imj.70415}
}
EUVIMED